N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population

被引:15
作者
Bialecka, M
Gawronska-Szklarz, B
Drozdzik, M
Honczarenko, K
Stankiewicz, J
机构
[1] Pomeranian Acad Med, Dept Pharmacol, PL-70111 Szczecin, Poland
[2] Pomeranian Acad Med, Dept Pharmacokinet & Therapeut Drug Monitoring, Szczecin, Poland
[3] Pomerian Acad Med, Dept Neurol, Szczecin, Poland
[4] Cty Hosp, Div Neurol, Szczecin, Poland
关键词
N-acetyltransferase; 2; polymorphism; Parkinson's disease;
D O I
10.1007/s00228-001-0415-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: A genetic background of Parkinson's disease has been suggested, including genes implicated in xenobiotic metabolism. So far, many candidate genes responsible for the occurrence of the disease have been enumerated. This study was carried out to determine the presence of N-acetyltransferase 2 polymorphism in Parkinson's disease patients in a Polish population. Methods: Fifty-four patients with diagnosed sporadic Parkinson's disease and 81 healthy individuals were enrolled into the study. The N-acetyltransferase 2 alleles (*4, *5 *6 and *7) were identified using polymerase chain reaction-restriction fragment length polymorphism methods with DNA extracted from peripheral blood. Results: A preponderance of slow acetylators in patients with Parkinson's disease was demonstrated. Among 54 subjects with parkinsonism, 64.8% were homozygous for two mutated alleles responsible for the slow-acetylator phenotype. In the control group, a predominance of fast acetylators was noted. Subjects homozygous and heterozygous with genotypes determining fast acetylation constituting 53% of subjects, whereas 47% were slow acetylators. Comparison of the two groups of the study, i.e. Parkinson's disease and healthy individuals, revealed a statistically significant predominance of slow acetylators in Parkinson's disease patients (P < 0.05). The risk of Parkinson's disease development was more than two times greater in slow acetylators than healthy subjects. The frequency of point mutations was similar both in patients with Parkinson's disease and the healthy controls. Conclusion: Slow-acetylation genotype may be an important factor of individual susceptibility to Parkinson's disease.
引用
收藏
页码:857 / 862
页数:6
相关论文
共 29 条
  • [21] Parkinson's disease, pesticides, and glutathione transferase polymorphisms
    Menegon, A
    Board, PG
    Blackburn, AC
    Mellick, GD
    Le Couteur, DG
    [J]. LANCET, 1998, 352 (9137) : 1344 - 1346
  • [22] Milejski P, 1999, Neurol Neurochir Pol, V33, P1015
  • [23] Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population
    Mrozikiewicz, PM
    Cascorbi, I
    Brockmoller, J
    Roots, I
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (04) : 376 - 382
  • [24] Riess O, 2000, J NEUROL, V247, P69
  • [25] Possible environmental, occupational, and other etiologic factors for Parkinson's disease: A case-control study in Germany
    Seidler, A
    Hellenbrand, W
    Robra, BP
    Vieregge, P
    Nischan, P
    Joerg, J
    Oertel, WH
    Ulm, G
    Schneider, E
    [J]. NEUROLOGY, 1996, 46 (05) : 1275 - 1284
  • [26] SPURR NN, 1995, CLIN CHEM, V12, P1864
  • [27] NOMENCLATURE FOR N-ACETYLTRANSFERASES
    VATSIS, KP
    WEBER, WW
    BELL, DA
    DUPRET, JM
    EVANS, DAP
    GRANT, DM
    HEIN, DW
    LIN, HJ
    MEYER, UA
    RELLING, MV
    SIM, E
    SUZUKI, T
    YAMAZOE, Y
    [J]. PHARMACOGENETICS, 1995, 5 (01): : 1 - 17
  • [28] GENETICALLY BASED N-ACETYLTRANSFERASE METABOLIC POLYMORPHISM AND LOW-LEVEL ENVIRONMENTAL EXPOSURE TO CARCINOGENS
    VINEIS, P
    BARTSCH, H
    CAPORASO, N
    HARRINGTON, AM
    KADLUBAR, FF
    LANDI, MT
    MALAVEILLE, C
    SHIELDS, PG
    SKIPPER, P
    TALASKA, G
    TANNENBAUM, SR
    [J]. NATURE, 1994, 369 (6476) : 154 - 156
  • [29] Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases
    Zielinska, E
    Niewiarowski, W
    Bodalski, J
    Stanczyk, A
    Bolanowski, W
    Rebowski, G
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (06) : 635 - 642